PT - JOURNAL ARTICLE AU - Liu, Hengcong AU - Zhang, Juanjuan AU - Cai, Jun AU - Deng, Xiaowei AU - Peng, Cheng AU - Chen, Xinghui AU - Yang, Juan AU - Wu, Qianhui AU - Chen, Xinhua AU - Chen, Zhiyuan AU - Zheng, Wen AU - Viboud, Cécile AU - Zhang, Wenhong AU - Ajelli, Marco AU - Yu, Hongjie TI - Herd immunity induced by COVID-19 vaccination programs and suppression of epidemics caused by the SARS-CoV-2 Delta variant in China AID - 10.1101/2021.07.23.21261013 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.23.21261013 4099 - http://medrxiv.org/content/early/2021/09/14/2021.07.23.21261013.short 4100 - http://medrxiv.org/content/early/2021/09/14/2021.07.23.21261013.full AB - Background To allow a return to a pre-COVID-19 lifestyle, virtually every country has initiated a vaccination program to mitigate severe disease burden and control transmission. However, it remains to be seen whether herd immunity will be within reach of these programs.Methods We developed a data-driven model of SARS-CoV-2 transmission for China, a population with low prior immunity from natural infection. The model is calibrated considering COVID-19 natural history and the estimated transmissibility of the Delta variant. Three vaccination programs are tested, including the one currently enacted in China and model-based estimates of the herd immunity level are provided.Results We found that it is unlike to reach herd immunity for the Delta variant given the relatively low efficacy of the vaccines used in China throughout 2021, the exclusion of underage individuals from the targeted population, and the lack of prior natural immunity. We estimate that, assuming a vaccine efficacy of 90% against the infection, vaccine-induced herd immunity would require a coverage of 93% or higher of the Chinese population. However, even when vaccine-induced herd immunity is not reached, we estimated that vaccination programs can reduce SARS-CoV-2 infections by 53-58% in case of an epidemic starts to unfold in the fall of 2021.Conclusions Efforts should be taken to increase population’s confidence and willingness to be vaccinated and to guarantee highly efficacious vaccines for a wider age range.Competing Interest StatementH.Y. has received research funding from Sanofi Pasteur, GlaxoSmithKline, Yichang HEC Changjiang Pharmaceutical Company, and Shanghai Roche Pharmaceutical Company. M.A. has received research funding from Seqirus. None of those research funding is related to COVID-19. All other authors report no competing interests.Funding StatementThe study was supported by grants from the National Science Fund for Distinguished Young Scholars (No. 81525023), European Union Grant 874850 MOOD (MOOD 000), and the National Institute for Health Research (NIHR) (grant no. 16/137/109) using UK aid from the UK Government to support global health research. We also acknowledge grant from Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response (20dz2260100). The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee approval was not needed in this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe availability of all data can be addressed to the correspondence author.